Are CRF receptor antagonists potential antidepressants?

Human Psychopharmacology

Volumn 16, Issue 1, 2001, Pages 81-87

  Paul, Ian A ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Antidepressants; Anxiety; CRF; CRF antagonists; Depression; Stress

Indexed keywords

2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; ANTALARMIN; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BETA ENDORPHIN; BRAIN PEPTIDE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; BUTYL[2,5 DIMETHYL 7 [2,4,6 TRIMETHYLPHENYL] 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; DESIPRAMINE; FLUOXETINE; GLUCOCORTICOID; IMIPRAMINE; LUTEINIZING HORMONE; MESSENGER RNA; RECEPTOR SUBTYPE; SC 241; UNCLASSIFIED DRUG; UROCORTIN;

AFFECTIVE NEUROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY NEUROSIS; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION; DEPRESSION; DRUG SOLUBILITY; DRUG STRUCTURE; ENDOCRINE SYSTEM; EVIDENCE BASED MEDICINE; EXPERIMENTAL ANIMAL; HUMAN; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MAMMAL; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; RECEPTOR AFFINITY; REGULATORY MECHANISM; STRESS;

EID: 0035104311     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.187     Document Type: Article

References (41)

1. The role of corticotropin-releasing factor in depression and anxiety disorders
2. 1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: In vivo evidence using a novel, selective, non-peptide CRF receptor antagonist
3. Corticotrophin-releasing factor receptors: From molecular biology to drug design
4. Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress
5. 1 receptor antagonists
6. The Impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress
7. Corticotropin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders
8. Physiological and behavioural responses to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress responses?
9. The role of corticotropin-releasing factor-norepinephrine systems in mediating the effects of early experience on the development of behavioral and endocrine responses to stress
10. Characterization of the behavioral profile of the non-peptide CRF antagonist CP-154,526 in anxiety models in rodents
11. Responses to corticotropin releasing hormone in the hypercortisolism of depression and Cushings disease: Pathophysiologic and diagnostic implications
12. Amygdaloid CRF pathways role in autonomic, neuroendocrine, and behavioral responses to stress
13. Small molecule CRF1 receptor antagonists: Characterization and clinical application
14. Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans
15. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety
16. The role of corticotropin-releasing factor in behavioural responses to stress
17. Distribution of urocortin-like immunoreactivity in the central nervous system of the rat
18. Functional neuroanatomy of the parvocellular vasopressinergic system: Transcriptional responses to stress and glucocorticoid feedback
19. The corticotropin-releasing factor stimulation test in patients with major depression: Relationship to dexamethasone suppression test results
20. Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation
21. Physiological and neurochemical aspects of corticotopin releasing factor actions in the brain: The role of the locus coeruleus
22. The ontogeny of the hypothalmic-pituitary-adrenal axis. The influence of maternal factors
23. 1 receptor antagonist
24. Recent advances with the CRF1 receptor: Design a small molecule inhibitors, receptor subtypes and clinical indications
25. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients
26. Reduced corticotropin-releasing factor binding sites in the frontal cortex of suicide victims
27. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy: Corticotropin-releasing factor, β-endorphin and somatostatin
28. Increased density of regional brain CRF binding sites after maternal deprivation
29. The preeminent role of early untoward experience on vulnerability to major psychiatric disorders: The nature-nurture controversy revisited and soon to be resolved
30. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA 1000 and CRA 1001
31. Physiology and pharmacology of corticotropin-releasing factor
32. Corticotropin-releasing factor antagonists. Therapeutic potential in the treatment of affective disorders
33. Neonatal separation alters HPA axis function, central CRF mRNA levels, behavior, and alcohol preferences in adult rats
34. Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients
35. Characterization of [1251] sauvagine binding to CRH 2 receptors: Membrane homogenate and autoradiographic studies
36. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors
37. 1 receptor attenuates stress-induced relapse to drug seeking in cocaine and heroin trained rats
38. Characterization of a 41 residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin
39. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor
40. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics
41. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation